Suzanne Nguyen Ph.D.

Suzanne Nguyen is an associate in Goodwin’s Life Sciences group, providing strategic intellectual property advice particularly for early stage life sciences companies and life sciences investors. Dr. Nguyen helps companies build and grow their patent portfolios and supports them during financing and transactions. Dr. Nguyen’s experience covers a wide array of technologies, including peptide or antibody-based therapeutics, radiopharmaceuticals, gene therapy, gene editing, epigenetics, immuno-oncology, cell therapies, and diagnostics.

Dr. Nguyen has been working in the field of intellectual property since 2007, beginning her career as a scientific advisor and then as a patent agent at another law firm. Dr. Nguyen also has previous in-house experience at a Swedish healthcare company.

• Represent Radiant Biotherapeutics, which is developing a modular multi-valent and multi-specific antibody engineering platform, in patent prosecution matters
• Represent Fusion Pharmaceuticals, which develops alpha-targeted radiopharmaceuticals, in patent prosecution matters
• Advise TVM Capital Life Science Management Inc. on IP due diligence matters in connection with new life sciences company formations, including in the $28 million investment in Mage Biologics
• Represent New York Stem Cell Foundation on patent prosecution matters relating generation of cell generation and screening systems
• Represent Ultragenyx Pharmaceutical in patent prosecution matters for AAV-based gene therapies
• Represented Turnstone Biologics, which develops oncolytic viral therapies, in patent prosecution matters and in connection with an investment from Takeda*
• Assisted in IP due diligence for Arix Bioscience in connection with a $58 million Series A financing of VelosBio, a clinical-stage company developing cancer therapies*
• Represented Editas Medicine, a gene editing company, in handling patent prosecution and assisted on matters in connection with their Initial Public Offering*
• Represented Flagship Pioneering in patent prosecution matters in connection with the formation of Omega Therapeutics, a company developing epigenomic controllers for therapeutic purposes*
• Assisted in successfully defending Shire Pharmaceuticals, which developed enzyme replacement therapies, in an Inter Partes Review proceeding*
• Represented Apellis Pharmaceuticals in patent prosecution matters related to peptide-based pharmaceuticals for ophthalmology indications*
• Represented HelixNano, a venture-backed startup using synthetic biology and machine learning to develop therapies and vaccines, in patent prosecution matters*
• As in-house patent agent, assisted Mölnlycke Health Care in European oppositions to third party patents*
• As in-house patent agent, assisted Mölnlycke Health Care in a diligence of electrochemical impedance spectroscopy (EIS)-based diagnostics technology from the University of Edinburgh and related negotiations with Scottish Enterprise*

*Denotes experience prior to joining Goodwin.

Dr. Nguyen previously served as an in-house patent advisor for Mölnlycke Health Care AB in Gothenburg, Sweden. In this role, Dr. Nguyen worked on cross-border transactions and managed relationships with universities and industry partners. Dr. Nguyen also collaborated closely with business development, research and development, and regulatory teams at Mölnlycke.

During her academic career, Dr. Nguyen studied the role of a DNA-modifying enzyme in nervous system development. Dr. Nguyen has also conducted research projects in the fields of immunology, cancer, and developmental biology, using genetic engineering and molecular biology techniques.

• Presenter, “Managing US Patent Prosecution from Abroad,” Global Patent Congress, Copenhagen, September 2014
• Presenter, “Developments in US Patent Law,”  Nordic Intellectual Property Rights Conference Stockholm, March 2014
• Author, “What Young Inventors Need to Know about Patents,”  Imagine Magazine (published by Johns Hopkins University Center for Talented Youth), February 2014
• Co-Author, “Ablation of de novo DNA methyltransferase Dnmt3a in the nervous system leads to neuromuscular defects and shortened lifespan,” Developmental Dynamics, June 2007
• Co-Author, “Suppression of Intestinal Neoplasia by Deletion of Dnmt3b,” Molecular and Cell Biology, 26(8): 2976-2983, April 2006
• Author, “Developmental Biology: A Field in Depth,” Imagine Magazine, December 2002
• Co-Author, “A Critical Role for Dnmt1 and DNA Methylation in T Cell Development, Function, and Survival,”  Immunity, 157(5): 763-774, November 2001
• Co-Author, “Requirement of Shp-2 Tyrosine Phosphatase in Lymphoid and Hematopoietic Cell Development,” Blood, 97(4): 911-914, February 2001
• Co-Author, “Promoter Element for Transcription of Unrearranged T-Cell Receptor Beta-Chain Gene in Pro-T Cells,” Blood, 93(9): 3017-3025, May 1999